Aveo no hit on its opening day – Boston Globe
|
Aveo no hit on its opening day
Boston Globe The disappointing market debut of Aveo, which develops cancer treatments, is the latest sign that hopes for a biotechnology IPO revival might be premature. … Aveo Pharmaceutical shares drop in trading debut AVEO Pharmaceuticals IPO Raises 23% Less Than Sought AVEO Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering |
